12 research outputs found
A phase I/II study of neoadjuvant chemotherapy with Pemetrexed (Alimta) in rectal cancer
Sealing ability of occlusal resin composite restoration using four restorative procedures
The purpose of this work was to investigate fluid flow after restoration using four restorative procedures. Micro-gap, internal dye leakage, and micropermeability of bonded interfaces were also investigated. Each tooth was mounted, connected to a fluid flow-measuring device, and an occlusal cavity was prepared. Fluid flow after cavity preparation was recorded as the baseline measurement, and the cavity was restored using one of four restorative procedures: bonding with total-etch (Single Bond 2) or self-etch (Clearfil SE Bond) adhesives without lining; or lining with resin-modified glass-ionomer cement (GIC) (Fuji Lining LC) or conventional GIC (Fuji IX) and then bonding with the total-etch adhesive. Fluid flow was recorded after restoration and at specific time-points up to 6 months thereafter and recorded as a percentage. Micro-gap formation was analyzed using resin replicas and scanning electron microscopy. Internal leakage of 2% methylene blue dye was observed under a light microscope. In micro-permeability testing, fluorescent-dye penetration was investigated using confocal laser microscopy. None of the restorative procedures provided a perfectly sealed restoration. Glass-ionomer lining did not reduce fluid flow after restoration, and micro-gaps were frequently detected. The self-etch adhesive failed to provide a better seal than the total-etch adhesive, and even initial gap formation was rarely observed for the former. Penetration of methylene blue and fluorescent dyes was detected in most restorations. © 2008 Eur J Oral Sci.link_to_subscribed_fulltex
Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
Background: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery. Methods: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) starting 12 h prior to surgery. The primary efficacy outcome was the incidence of VTE (detected by bilateral venography or symptomatic events) during treatment. Results: Of the 1949 treated patients, 1464 (75%) patients were evaluable for the efficacy analysis. VTE occurred in 28.5%, 17.4%, 16.6%, 13.1% and 24% of patients assigned to dabigatran etexilate 50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily and enoxaparin, respectively. A significant dose-dependent decrease in VTE occurred with increasing doses of dabigatran etexilate (P <0.0001). Compared with enoxaparin, VTE was significantly lower in patients receiving 150 mg twice daily [odds ratio (OR) 0.65, P = 0.04], 300 mg once daily (OR 0.61, P = 0.02) and 225 mg twice daily (OR 0.47, P = 0.0007). Compared with enoxaparin, major bleeding was significantly lower with 50 mg twice daily (0.3% vs. 2.0%, P = 0.047) but elevated with higher doses, nearly reaching statistical significance with the 300 mg once-daily dose (4.7%, P = 0.051). Conclusions: Oral administration of dabigatran etexilate, commenced early in the postoperative period, was effective and safe across a range of doses. Further optimization of the efficacy/safety balance will be addressed in future studie
Comparison of folate derivate levels in mucosa and tumor tissue in the course of antifolate treatment with pemetrexed.
Short periods of oscillating fluid pressure directed at a titanium-bone interface in rabbits lead to bone lysis
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)
BACKGROUND: Anticoagulant prophylaxis substantially reduces the risk of venous thromboembolism (VTE) after major orthopedic surgery. The direct factor Xa inhibitor YM150 is currently under investigation for the prevention of VTE, stroke and ischemic vascular events in patients after orthopedic surgery, with atrial fibrillation and with acute coronary syndrome, respectively. OBJECTIVES: To investigate the efficacy and safety of YM150 for the prevention of VTE following elective total hip arthroplasty. PATIENTS/METHODS: Patients were randomized to postoperative, once-daily, oral YM150 (5, 10, 30, 60 or 120 mg) (double-blind) or preoperative subcutaneous (open label) enoxaparin (40 mg) for 5 weeks. The primary efficacy endpoint comprised VTE diagnosed by mandatory bilateral venography or verified symptomatic deep vein thrombosis (DVT) plus all deaths up to 9 days after surgery. The primary safety outcome was major bleeding up to 9 days after surgery. RESULTS: Primary efficacy endpoint: of 1017 patients randomized, 960 patients were evaluable for safety and 729 patients for efficacy. A dose-related decrease in VTE incidence from YM150 5 to 60 mg (P = 0.0005) and from 5 to 120 mg (P = 0.0002) was found. The VTE incidence was 27.4%, 31.7%, 19.3%, 13.3% and 14.5% for 5, 10, 30, 60 and 120 mg YM150, respectively, and 18.9% for enoxaparin. Primary safety endpoint: there was one major bleed with YM150 (60 mg) and one with enoxaparin. CONCLUSIONS: The oral direct FXa inhibitor YM150 demonstrated a significant dose response regarding efficacy. Doses from 30 to 120 mg had comparable efficacy to enoxaparin, without compromising safety regarding major bleeding event